Based on three prospective randomized trials showing clinical or survival benefit for adjuvant radiotherapy in patients with pathological T3 disease or positive margins, adjuvant radiotherapy is recommended to PCa patients with high-risk of local recurrence when the PSA is undetectable (< 0.2 ng/mL) [28–31]. Here, KLK3 is linked to posterior cortical atrophy.